Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$11.12
-0.7%		$6.89
$2.74
▼
$11.65
$3.49B1.29.40 million shs8.18 million shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$15.27
+1.1%		$13.31
$4.68
▼
$17.25
$928.09M1.63430,490 shs917,955 shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$80.05
+1.5%		$74.86
$1.16
▼
$14.10
$3.47B-0.12189,291 shs384,206 shs
uniQure N.V. stock logo
QURE
uniQure
$47.38
-1.2%		$42.10
$8.73
▼
$71.50
$3.37B0.931.42 million shs501,292 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-0.71%+13.93%+71.87%+143.33%+138.12%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
+1.13%+4.45%+21.48%+37.57%+182.78%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
+1.53%+2.26%+5.12%+24.94%+33.73%
uniQure N.V. stock logo
QURE
uniQure
-1.23%+5.29%+17.71%+92.60%+202.55%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$11.12
-0.7%		$6.89
$2.74
▼
$11.65
$3.49B1.29.40 million shs8.18 million shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$15.27
+1.1%		$13.31
$4.68
▼
$17.25
$928.09M1.63430,490 shs917,955 shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$80.05
+1.5%		$74.86
$1.16
▼
$14.10
$3.47B-0.12189,291 shs384,206 shs
uniQure N.V. stock logo
QURE
uniQure
$47.38
-1.2%		$42.10
$8.73
▼
$71.50
$3.37B0.931.42 million shs501,292 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-0.71%+13.93%+71.87%+143.33%+138.12%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
+1.13%+4.45%+21.48%+37.57%+182.78%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
+1.53%+2.26%+5.12%+24.94%+33.73%
uniQure N.V. stock logo
QURE
uniQure
-1.23%+5.29%+17.71%+92.60%+202.55%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.71
Moderate Buy$12.8315.41% Upside
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
2.88
Moderate Buy$16.508.06% Upside
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
2.71
Moderate Buy$65.0037.19% Upside

Current Analyst Ratings Breakdown

Latest DSGN, ABCL, GMTX, and QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$12.00 ➝ $30.00
8/6/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $9.00
8/6/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$11.00 ➝ $12.00
7/30/2026
uniQure N.V. stock logo
QURE
uniQure
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$65.00 ➝ $60.00
7/30/2026
uniQure N.V. stock logo
QURE
uniQure
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$60.00 ➝ $75.00
7/29/2026
uniQure N.V. stock logo
QURE
uniQure
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$65.00
7/17/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/7/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy$11.00
6/29/2026
uniQure N.V. stock logo
QURE
uniQure
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$50.00 ➝ $80.00
6/26/2026
uniQure N.V. stock logo
QURE
uniQure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$75.13M45.38N/AN/A$3.23 per share3.44
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/A$3.73 per shareN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
uniQure N.V. stock logo
QURE
uniQure
$16.10M204.15N/AN/A$3.19 per share14.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.54N/AN/AN/A-248.83%-17.49%-12.36%11/5/2026 (Estimated)
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$69.79M-$1.18N/AN/AN/AN/A-34.03%-32.05%11/4/2026 (Estimated)
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$4.01N/AN/AN/A-1,350.73%-111.96%-29.01%N/A

Latest DSGN, ABCL, GMTX, and QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1640-$0.18-$0.0160-$0.18$7.85 million$4.05 million
8/3/2026Q2 2026
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.3443-$0.32+$0.0243-$0.32N/AN/A
7/29/2026Q2 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.8223-$1.22-$0.3977-$1.22$5.45 million$5.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
12.77
12.77
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/A
18.86
18.86
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
uniQure N.V. stock logo
QURE
uniQure
0.15
10.01
10.01

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
56.64%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
uniQure N.V. stock logo
QURE
uniQure
78.83%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
17.10%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
uniQure N.V. stock logo
QURE
uniQure
4.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500306.61 million219.53 millionOptionable
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
4062.58 million51.88 millionOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
uniQure N.V. stock logo
QURE
uniQure
50069.37 million66.14 millionOptionable

Recent News About These Companies

Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-increases-stock-position-in-uniqure-nv-qure-2026-08-19/
uniQure Charts Accelerated Path With AMT‑130
August 16 at 8:30 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/uniqure-charts-accelerated-path-with-amt130?utm_source=marketbeat.com&utm_medium=referral
Wall Street Zen Upgrades uniQure (NASDAQ:QURE) to "Hold"
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961524
uniQure (NASDAQ:QURE) Upgraded by Wall Street Zen to "Hold" Rating
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/uniqure-nasdaqqure-upgraded-by-wall-street-zen-to-hold-rating-2026-08-15/
Hennion & Walsh Asset Management Inc. Increases Holdings in uniQure N.V. $QURE
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hennion-walsh-asset-management-inc-increases-holdings-in-uniqure-nv-qure-2026-08-10/
Assenagon Asset Management S.A. Has $23.65 Million Position in uniQure N.V. $QURE
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-has-2365-million-position-in-uniqure-nv-qure-2026-08-10/
uniQure (QURE) Q2 2026 Earnings Call Transcript
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/uniqure-qure-q2-2026-earnings-003509635.html
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Brokerages
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/uniqure-nv-nasdaqqure-given-average-rating-of-moderate-buy-by-brokerages-2026-08-07/
Militia Capital Management LLC Invests $1.54 Million in uniQure N.V. $QURE
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-militia-capital-management-llc-invests-154-million-in-uniqure-nv-qure-2026-08-03/
Equities Analysts Issue Forecasts for uniQure Q3 Earnings
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/equities-analysts-issue-forecasts-for-uniqure-q3-earnings-2026-08-03/
uniQure (NASDAQ:QURE) Stock Rating Lowered by Wall Street Zen
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/uniqure-nasdaqqure-stock-rating-lowered-by-wall-street-zen-2026-08-01/
uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course
July 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928942-uniqure-hold-amt-130-u-turn-by-fda-for-hd-could-possibly-alter-course?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Barclays Keeps Their Buy Rating on uniQure (QURE)
July 31, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/QURE/pressreleases/3571191/barclays-keeps-their-buy-rating-on-uniqure-qure/
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
July 31, 2026  |  biospace.comB
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
July 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2964752/qure-q2-earnings-miss-estimates-on-higher-costs-revenues-rise-y-y?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2964752
Wells Fargo & Company Issues Positive Forecast for uniQure (NASDAQ:QURE) Stock Price
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wells-fargo-company-issues-positive-forecast-for-uniqure-nasdaqqure-stock-price-2026-07-30/
uniQure N.V. (QURE) Q2 2026 Earnings
July 30, 2026  |  247wallst.comhttps://247wallst.com/cards/uniqure-n-v-q2-2026-earnings-qure-01kypscy2phm6k6d1zs7kb1j4j
UniQure outlines AMT-130 BLA this quarter, supported by cash runway into 2030
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4620738-uniqure-outlines-amtminus-130-bla-this-quarter-supported-by-cash-runway-into-2030
AdCom expected for uniQure’s Huntington’s gene therapy, chief medical officer says
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/adcom-expected-uniqure-huntington-gene-154916146.html
Stempoint Capital LP Has $1.28 Million Stock Position in uniQure N.V. $QURE
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-stempoint-capital-lp-has-128-million-stock-position-in-uniqure-nv-qure-2026-07-30/
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
July 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927181-uniqure-n-v-qure-q2-2026-earnings-call-transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$11.12 -0.08 (-0.71%)
Closing price 08/18/2026 04:00 PM Eastern
Extended Trading
$11.32 +0.21 (+1.84%)
As of 08:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Design Therapeutics stock logo

Design Therapeutics NASDAQ:DSGN

$15.27 +0.17 (+1.13%)
Closing price 08/18/2026 04:00 PM Eastern
Extended Trading
$15.27 0.00 (0.00%)
As of 08/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$80.05 +1.21 (+1.53%)
As of 08/17/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

uniQure stock logo

uniQure NASDAQ:QURE

$47.38 -0.59 (-1.23%)
Closing price 08/18/2026 04:00 PM Eastern
Extended Trading
$47.50 +0.13 (+0.26%)
As of 08:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas